IDEXX Laboratories Stock News

Baron Asset Fund underperformed for a second consecutive quarter as U.S. equities continued their strong rally from the market lows reached on April 8. From a sector perspective, stock selection in IT and Communication Services was responsible for about three-quarters of the underperformance in the period. Stock selection in Consumer Discretionary, Financials, and Industrials hampered relative ...

No single month beats November for S&P 500 stock market performance. And a handful of stocks are already taking off.

IDEXX Laboratories (IDXX) continues to outperform the S&P 500, driven by strong recurring revenue and a robust customer ecosystem. IDXX delivered a double beat in Q3, with revenue up 13% and EPS up 21%, alongside expanding margins and reduced debt. International growth, new product launches like InVueDx, and ongoing share buybacks are key catalysts for future performance.

IDEXX Laboratories (NASDAQ: IDXX) extended its streak of earnings beats this morning, reporting Q3 results that topped both EPS and revenue expectations while raising full-year guidance.

It notched a beat-and-raise third quarter. It cited innovation and increased customer take-up as reasons for the solid growth it posted during the frame.

IDEXX Laboratories, Inc. ( IDXX ) Q3 2025 Earnings Call November 3, 2025 8:30 AM EST Company Participants Andrew Emerson - Executive VP, CFO & Treasurer Jay Mazelsky - President, CEO & Director Conference Call Participants Erin Wilson Wright - Morgan Stanley, Research Division Michael Ryskin - BofA Securities, Research Division Jonathan Block - Stifel, Nicolaus & Company, Incorporated, Research...

Vet visits are down, but growing revenue per visit is more than making up for it, the company says.

Idexx Laboratories catapulted to a record high Monday after the vet diagnostics outlet beat quarterly forecasts and boosted its 2025 outlook.